Jaguar Health Celebrates National Service Dog Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs
Jaguar Health (NASDAQ:JAGX) is celebrating National Service Dog Month, highlighting its commitment to supportive cancer care for both humans and dogs. The company's FDA conditionally approved drug, Canalevia-CA1, is the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs.
Canalevia-CA1, a canine-specific formulation of crofelemer, is available by prescription from veterinarians and on Chewy. Jaguar's ongoing 'Make Cancer Less Shitty' campaign emphasizes the challenges of cancer treatments, especially for metastatic patients. The campaign features patient ambassadors sharing their experiences on the website makecancerlessshitty.com and on X under the handle cancersuckless.
Jaguar's CEO, Lisa Conte, stressed the alignment between service dogs' role in improving quality of life and Jaguar's mission to provide supportive care for complex diseases like cancer in both people and dogs.
Jaguar Health (NASDAQ:JAGX) celebra il Mese Nazionale dei Cani di Servizio, evidenziando il suo impegno per una cura oncologica di supporto sia per gli esseri umani che per i cani. Il farmaco approvato con riserva dalla FDA dell'azienda, Canalevia-CA1, è il primo e unico trattamento per la diarrea indotta da chemioterapia (CID) nei cani.
Canalevia-CA1, una formulazione specifica per canini di crofelemer, è disponibile su prescrizione dai veterinari e su Chewy. La campagna in corso di Jaguar 'Make Cancer Less Shitty' sottolinea le sfide dei trattamenti oncologici, in particolare per i pazienti metastatici. La campagna presenta ambasciatori pazienti che condividono le loro esperienze sul sito web makecancerlessshitty.com e su X con l'handle cancersuckless.
Il CEO di Jaguar, Lisa Conte, ha sottolineato l'allineamento tra il ruolo dei cani di servizio nel migliorare la qualità della vita e la missione di Jaguar di fornire cure di supporto per malattie complesse come il cancro sia per le persone che per i cani.
Jaguar Health (NASDAQ:JAGX) celebra el Mes Nacional del Perro de Servicio, destacando su compromiso con el cuidado del cáncer de apoyo tanto para humanos como para perros. El medicamento aprobado condicionalmente por la FDA de la compañía, Canalevia-CA1, es el primer y único tratamiento para la diarrea inducida por quimioterapia (CID) en perros.
Canalevia-CA1, una formulación específica para perros de crofelemer, está disponible con receta de veterinarios y en Chewy. La campaña actual de Jaguar 'Make Cancer Less Shitty' enfatiza los desafíos de los tratamientos contra el cáncer, especialmente para pacientes metastásicos. La campaña presenta embajadores pacientes que comparten sus experiencias en el sitio web makecancerlessshitty.com y en X bajo el nombre de usuario cancersuckless.
La CEO de Jaguar, Lisa Conte, enfatizó la alineación entre el papel de los perros de servicio en la mejora de la calidad de vida y la misión de Jaguar de proporcionar atención de apoyo para enfermedades complejas como el cáncer, tanto en personas como en perros.
재규어 헬스(Jaguar Health, NASDAQ:JAGX)는 국가 서비스 개의 달을 기념하며 인간과 개 모두에 대한 지원 암 치료에 대한 헌신을 강조합니다. 회사의 FDA 조건부 승인 약물인 카날레비아-CA1은 개의 화학요법 유발 설사(CID)에 대한 첫 번째이자 유일한 치료제입니다.
카날레비아-CA1은 개 전용 크로펠레머 제형으로, 수의사의 처방을 통해 Chewy에서 구입할 수 있습니다. 재규어의 현재 진행 중인 캠페인 'Make Cancer Less Shitty'은 특히 전이 환자에게 있어 암 치료의 어려움을 강조합니다. 이 캠페인은 환자 대사들이 웹사이트 makecancerlessshitty.com 및 X에서 계정 cancersuckless를 통해 그들의 경험을 공유하는 모습을 담고 있습니다.
재규어의 CEO인 리사 콘트(Lisa Conte)는 삶의 질을 개선하는 서비스 개의 역할과 재규어가 사람과 개 모두를 위한 복잡한 질병, 특히 암의 지원 치료를 제공하는 사명이 일치한다는 점을 강조했습니다.
Jaguar Health (NASDAQ:JAGX) célèbre le Mois National des Chiens de Service, soulignant son engagement envers des soins de soutien au cancer tant pour les humains que pour les chiens. Le médicament conditionnellement approuvé par la FDA de l'entreprise, Canalevia-CA1, est le premier et le seul traitement pour la diarrhée induite par la chimiothérapie (CID) chez les chiens.
Canalevia-CA1, une formulation spécifique pour chiens de crofelemer, est disponible sur ordonnance auprès des vétérinaires et sur Chewy. La campagne en cours de Jaguar 'Make Cancer Less Shitty' met en avant les défis des traitements contre le cancer, en particulier pour les patients métastatiques. La campagne présente des ambassadeurs patients partageant leurs expériences sur le site web makecancerlessshitty.com et sur X sous le pseudo cancersuckless.
La PDG de Jaguar, Lisa Conte, a souligné l'alignement entre le rôle des chiens de service dans l'amélioration de la qualité de vie et la mission de Jaguar de fournir des soins de soutien pour des maladies complexes comme le cancer tant chez les personnes que chez les chiens.
Jaguar Health (NASDAQ:JAGX) feiert den Nationalen Diensthundemonat und hebt sein Engagement für unterstützende Krebsbehandlungen sowohl für Menschen als auch für Hunde hervor. Das von der FDA bedingt zugelassene Medikament des Unternehmens, Canalevia-CA1, ist die erste und einzige Behandlung für chemotherapiebedingten Durchfall (CID) bei Hunden.
Canalevia-CA1, eine hundespezifische Formulierung von Crofelemer, ist nur auf Rezept von Tierärzten und bei Chewy erhältlich. Die laufende Kampagne von Jaguar 'Make Cancer Less Shitty' betont die Herausforderungen der Krebsbehandlungen, insbesondere für metastasierte Patienten. Die Kampagne verfügt über Patientenbotschafter, die ihre Erfahrungen auf der Website makecancerlessshitty.com und auf X unter dem Handle cancersuckless teilen.
Die CEO von Jaguar, Lisa Conte, betonte die Übereinstimmung zwischen der Rolle von Diensthunden zur Verbesserung der Lebensqualität und dem Ziel von Jaguar, unterstützende Behandlungen für komplexe Krankheiten wie Krebs sowohl bei Menschen als auch bei Hunden anzubieten.
- None.
- None.
Company's Canalevia®-CA1 prescription drug is FDA conditionally approved for treatment of chemotherapy-induced diarrhea (CID) in dogs and is the first and only treatment for CID in dogs to receive any type of approval from FDA
SAN FRANCISCO, CA / ACCESSWIRE / September 5, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") is proud to be celebrating National Service Dog Month, a time devoted to raising awareness and showing appreciation for the extraordinary work service dogs do every day for the people in their care.
"September is National Service Dog Month. Service dogs are incredible working animals who enable people to live more independently and enjoy a better quality of life. In some cases, service dogs can be the difference between life and death," said Lisa Conte, Jaguar's founder, president, and CEO. "These qualities align with Jaguar's mission of providing supportive care to people and dogs suffering from complex disease states like cancer."
Canalevia®-CA1, Jaguar's U.S. Food and Drug Administration (FDA) conditionally approved prescription drug product for the treatment of chemotherapy-induced diarrhea (CID) in dogs, is available on Chewy and from veterinarians across the U.S. By prescription only, Canalevia-CA1 is a canine-specific formulation of crofelemer, Jaguar's novel, oral plant-based product sustainably harvested from the Croton lechleri tree.
"Our deep commitment to supportive cancer care is a core message of our ongoing "Make Cancer Less Shitty" campaign, which seeks to broadly acknowledge the rigors of both short-term and perpetual cancer treatments for metastatic patients. We thankfully now live in the age of targeted therapies for cancer treatment, and thanks to these amazing drugs, cancer patients and metastatic cancer patients are living longer - 5, 10, 20 years longer - frequently rendering cancer a chronic ailment with which to live," Conte said. "The "Make Cancer Less Shitty" campaign allows cancer patients to share their voices and stories - their lived experience. We launched the campaign with three remarkable patient ambassadors, and you can find their stories and our commitment on the campaign website: makecancerlessshitty.com. The primary social media channel for the campaign is X, under the handle cancersuckless."
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.
For more information about:
Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit www.napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Magdalena Biosciences, visit magdalenabiosciences.com
Visit the Make Cancer Less Shitty patient advocacy program at makecancerlessshitty.com and on X, Facebook & Instagram
Important Safety Information About Canalevia-CA1
For oral use in dogs only. Not for use in humans. Keep Canalevia-CA1 (crofelemer delayed-release tablets) in a secure location out of reach of children and other animals. Consult a physician in case of accidental ingestion by humans. Do not use in dogs that have a known hypersensitivity to crofelemer. Prior to using Canalevia-CA1, rule out infectious etiologies of diarrhea. Canalevia-CA1 is a conditionally approved drug indicated for the treatment of chemotherapy-induced diarrhea in dogs. The most common adverse reactions included decreased appetite, decreased activity, dehydration, abdominal pain, and vomiting.
Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed. It is a violation of Federal law to use this product other than as directed in the labeling.Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
CONTACT:
hello@jaguar.health
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View the original press release on accesswire.com
FAQ
What is Jaguar Health's Canalevia-CA1 used for in dogs?
Where can I purchase Jaguar Health's Canalevia-CA1 for my dog?
What is Jaguar Health's 'Make Cancer Less Shitty' campaign about?
How is Jaguar Health (JAGX) celebrating National Service Dog Month in 2024?
What is the main ingredient in Jaguar Health's Canalevia-CA1?
